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Introduction 
Glioblastoma multiforme (GBM) is the most common 
primary brain tumour in adults. It is also classified as 
grade IV glioma which arises from the lineage of star-
shaped glial cells known as astrocytes. The survival 
rate is very poor where only 15% of patients survived 
more than 24 months due to disease aggressiveness 
and heterogeneity of the disease [1, 2]. Although 
several molecular inhibitors have been developed to 
target aberrantly expressed enzymes and proteins, the 
results have been very frustrating [3, 4]. Factors 
contributing to resistant of GBM cells include 
deregulation of key signalling pathways, namely 
PTEN, TP53, RB and PI3K-Akt [5, 6], increased in the 
expression of anti-apoptotic proteins BCL2 and 
survivin [7, 8], iterative perivascular growth within the 
highly vascularized brain [9], and presence of 30-65% 
constitutively active EGFRvIII mutant in GBM which 
secretes higher levels of invasion-promoting proteins 
[10](Sangar et al., 2014). Studies have revealed that 
Tousled-like kinase 1 (TLK1) is overexpressed in 
breast cancer [11], prostate cancer [12], and 
cholangiocarcinoma [13]. In our unpublished study, 
we proved that TLK1 is overexpressed in GBM and 
silencing of TLK1 results in a significant decrease in 
invasion, migration and GBM cells survival [14]. 
 
Human TLK1 contains 766 amino acids and is one of 
the members of the Tousled-like kinase family 
consisting of TLK1 and TLK2 [15]. The gene is 
mapped on chromosome 2q31.1 and encoded by 25 
exons. TLK1 share 85% sequence identity to TLK2, 
and both share ~50% sequence identity with 
Arabidopsis thaliana where Tousled-like kinase 
family was initially identified [16]. This serine-
threonine kinase is an important signalling regulator 
mainly involved in the cell cycle regulation, cellular 
mitosis, cell survival, and proliferation [17]. In 
general, the N-terminal domain of Tousled-like kinase 
is well conserved to include three potential nuclear 
localization sequences and three putative coiled-coil 
regions, while the C-terminus region contains the 
catalytic ATP-binding domain at the region that 
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Abstract 
 
Glioblastoma multiforme (GBM) is a high-grade brain tumor of which the survival patients remain poor. 
Tousled-like kinase 1 (TLK1), a serine-threonine kinase, was identified to be overexpressed in cancers such 
as GBM. TLK1 plays an important role in controlling survival pathways. To date, there is no structure 
available for TLK1 as well as its inhibitors. We aimed to create a homology model of TLK1 and to identify 
suitable molecular inhibitors that are likely to bind and inhibit TLK1 activity via in silico high-throughput 
virtual screening (HTVS) protein-ligand docking. The 3D homology models of TLK1 were derived from 
various servers. All models were evaluated using Swiss Model QMEAN server. Validation was performed 
using multiple tools. Energy minimization was performed using YASARA. Subsequently, HTVS was 
performed using Molegro Virtual Docker 6.0 and ligands derived from ligand.info database. Drug-like 
molecules were filtered using ADME-Tox filtering program. Best homology model was obtained from the 
Aurora B kinase (PDB ID:4B8M) derived from Xenopus levias structure that share sequence similarity with 
human TLK1. Two compounds were identified from HTVS to be the potential inhibitors as it did not violate 
the Lipinski rule of five and the CNS-based filter as a potential drug-like molecule for GBM. 
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consists of 456 to 734 amino acid residues. The active 
binding site is located within the protein kinase 
domain sequence [18]. This ~90 kDa kinase is 
activated by the CHK1/ATM DNA damage pathway 
[19]. TLK1 interacts with its substrates, namely Asf1, 
histone H3 [20], and Rad9 [17] to activate DNA 
damage and DNA repair activity [21]. It was suggested 
that when overexpressed, TLK1 is involved in 
radioprotection and chemo-resistance of cancer cells 
[22]. Unfortunately, the structure of TLK1 has not 
been elucidated and this hinders the full understanding 
of TLK1 biological processes. Nonetheless, the X-ray 
diffraction data for the kinase domain of human TLK1 
family member TLK2 have been recently reported 
which may shed a light on structural understanding of 
human Tousled-like kinase [23]. No structure is yet 
available for both TLK1 and TLK2, hence, we 
perform a homology modelling study of TLK1 
structure to understand its function in orchestrating 
cellular functions particularly in cancer pathways. In 
this study, we present a structural homology model of 
the TLK1 catalytic binding domain which may serve 
as a potential target for molecular inhibitors. We then 
used the proposed structure to identify potential 
inhibitors for TLK1 by utilising in silico ligand-
docking with high throughput virtual screening 
(HTVS) targeting more than 16,000 candidate 
compounds. 
 
 
Materials and methods 
Template identification and homology modelling 
The amino acid sequence of human TLK1 was 
retrieved from UniProt with the accession number: 
Q9UKI8 (http://www.uniprot.org/). The TLK1 
FASTA format amino acid sequence was downloaded 
into the BLASTP and PSI-BLAST search 
(http://blast.ncbi.nlm.nih.gov/) in order to identify 
homologous proteins. The appropriate template for 
TLK1 was blasted against pdb database. Query 
identified suitable template based on the E-value of 
2e-26 to 2e-22 and sequence identity ranging from 
30% to 33% at the protein kinase catalytic domain 
indicating similarity of structure and function. The 
template and the target sequences were later aligned 
using the Clustal Omega program 
(http://www.ebi.ac.uk/Tools/msa/clustalo/). 
Subsequently, homology modelling was carried out 
against the chosen template using HOmology 
ModellER [24], I-Tasser [25], and PsiPred [26]. 
Analysis were performed in October 2013 until 
January 2014. 
 
Homology models quality estimation 
We used 20 pdb files created and generated from two 
homology modelling servers; Homology modeller 
(HOMER) and i-Tasser to further estimate and ensure 
appropriate model selected are in good quality. The 
model quality estimation was performed using the 
Swiss-Model Qualitative Model Energy Analysis 
(QMEAN) Server 
(https://swissmodel.expasy.org/qmean/), of which the 
composite scoring function, derives a quality 
estimation on the basis of the geometrical analysis of 
single models [27]. It also describes the major 
geometrical aspects of the protein structures. Five 
different structural descriptors were used. The local 
geometry was analyzed using the torsion angle 
potential function over three consecutive amino acids. 
A secondary structure-specific distance-dependent 
pairwise residue-level potential was used to assess 
long-range interactions. A solvation potential 
describes the burial status of the residues. Two simple 
terms describing the agreement of predicted and 
calculated secondary structure and solvent 
accessibility, were also included. In comparison with 
other protein structure evaluation servers, the 
QMEAN shows a statistically significant 
improvement over nearly all quality measures 
describing the ability of the scoring function to 
identify the native structure and to discriminate good 
from bad models [28]. 3D structure was then 
visualized using PyMol software (The PyMOL 
Molecular Graphics System, Version 1.5.0.4 
Schrödinger, LLC). 
Validation of modelled structure 
The best homology model created was used for further 
investigation. We used the latest version of PDBsum 
(http://www.ebi.ac.uk/thornton-
srv/databases/pdbsum/) which provides further 
information on protein function prediction, structural 
topology, PROCHECK and cleft analysis. We also 
used ProSA which displays scores and energy plots 
that highlight potential problems spotted in protein 
structures [29]. Prediction of the protein structure 
function was performed using proteo-genomic 
analysis software 3d2go 
(http://www.sbg.bio.ic.ac.uk/phyre/pfd/html/help.htm
l). This allowed full structural scan of the protein 
structure made against the Structural Classification of 
Proteins (SCOP) database using a modified version of 
BLAST [30]. Energy minimization was performed on 
YASARA server 
(http://www.yasara.org/minimizationserver.php). 
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High throughput in silico ligand-docking analysis 
In silico ligand-docking analysis was performed using 
Molegro Virtual Docker (MVD version 2013.6.0) to 
predict protein-ligand interactions. The potential 
binding sites of selected proteins and candidate small 
molecules were characterized by the molecular 
docking algorithm called MolDock which was derived 
from “Piecewise Linear Potential [31]. The MolDock 
score refers to the approximate binding energies 
between protein and ligand which is usually expressed 
in kcal/mol.  This software handles all aspects of the 
docking process from the preparation of the molecules 
to determine the potential binding site of the target 
protein, and the predicted binding modes of the ligand. 
Interestingly, MVD has been shown to provide higher 
accuracy compared with the other commercially 
available docking softwares e.g. Glide, Surflex and 
FlexX [32]. Docking requires five steps; importing 
molecules, importing ligands, molecular preparation, 
creating template and docking.  
Candidate ligands for ligand-docking screening were 
downloaded from Ligand.Info (http://ligand.info/) 
which compiles various publicly available databases 
of small molecules and compounds from ChemBank, 
KEGG, ChemPDB, Drug-likeness NCI subset and 
non-annotated NCI subset [33]. We downloaded a 
total of 16,358 sdf. format small molecules from 
KEGG ligands (10,005), ChemBank (2,344) and 
ChemPDB (4,009) for high throughput screening of 
potential inhibitors for TLK1. Due to the large number 
of candidate KEGG ligands, we filtered out some of 
these compounds based on the relevancy to the present 
TLK1 3D model using Findsite server [34] as a pre-
molecular docking step. After filtering these ligands, 
only 1,386 KEGG ligands were selected for further 
investigation. Most of the ligands in the database as 
well as the homology model or molecule did not have 
correct bond orders and bond angles. Hence, full 
optimization of molecules and ligand preparation was 
performed using Molegro Virtual Docking software 
default setting whereby appropriate missing hydrogen 
atoms were added, missing bonds were assigned, 
partial charges were added if necessary and flexible 
torsions in ligands detected.  
Docking study was performed at the catalytic domain 
of TLK1. Simulation on the modelled protein 
identified five cavities as potential binding sites. 
However, only one cavity was used for the ligand-
docking study i.e. the cavity with the largest surface 
area and volume of 214.528 arbitary unit within the 
catalytic domain sites of TLK1. The predicted sites 
had a grid resolution of 0.3Å and a binding site of 15Å 
radius from the template. The Moldock optimizer was 
used as a search algorithm and the number of runs was  
 
set to 10 with a maximum iteration of 1000, scaling 
factor of 0.50, 0.90 cross over and a population size of 
50. The maximum number of poses generated was 5. 
Potential ligands were selected based on the best 
MolDock score value that is less than -170. 
Visualization of ligand-protein interaction 
The three-dimensional and two-dimensional 
visualisation of ligand-protein interaction were 
performed using the Maestro software package 
(Maestro, version 10.4, Schrödinger, LLC, New York, 
NY, 2015). 
In silico bioavailability study 
Lead molecules identified from the high throughput 
ligand-docking screening were subjected to further in 
silico filtering to identify those with the best values in 
terms of their absorption, distribution, metabolism, 
excretion and toxicity (ADME-Tox). This was done 
using the FAF-Drugs3 (November 2014 edition) 
which is a free ADME-Tox [35] filtering tool. This 
step will ensure the suitability of lead molecules based 
on toxicity for future in vivo applications. We applied 
Lipinski’s Rule of Five [36] to remove some reactive 
groups and compounds. We have also included the 
Central Nervous System (CNS) drugs 
physicochemical criteria [37, 38], which includes (1) 
molecular mass less than 450 Da, (2) partition 
coefficient (logP) of 0.2 -6.0, (3) hydrogen bond 
donors not less than three, (4) hydrogen bond 
acceptors not less than five and (5) topological surface 
area (tPSA) within 3-118. 
 
Results 
Homology modelling of TLK1 serine/threonine kinase 
 
The PSI-BLAST results of TLK1 sequence Q9UKI8 
were analysed and we selected the protein hits based 
on query coverage, similarity and identity. The model 
structure which was selected showed sequence 
identity and similarity that ranged from 27% to 37% 
and a query coverage E-value that ranged from 4e-29 
to 9e-15 and covered only the protein kinase domain 
site (450-756). The homology model was created 
based on the TLK1 protein kinase catalytic domain 
sequence. We selected 40 protein sequence templates 
for homology modelling using various softwares. 
However, only 18 models were successfully created 
using HOmology ModellER and i-tasser. We 
evaluated all the 18 models using QMEAN Server and 
identified the Aurora B kinase structure from African 
clawed frog Xenopus levias (PDB ID: 4B8M) as the 
best template structure for TLK1 producing a total 
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Table 1. Top 20 models generated from two homology modelling servers; Homology modeller (HOMER) and i-
Tasser. TLK1homer4B8M was selected as our homology model for subsequent analysis. 
 
Model name 
C_beta 
interaction 
energy 
All-atom 
pairwise 
energy 
Solvation 
energy 
Torsion 
angle 
energy 
Secondary 
structure 
agreement 
Solvent 
accessibility 
agreement 
Total 
QMEAN-
score 
 
TLK1homer4B8M -61 -5727.18  -16.37  -16.13 89.30% 79.30% 0.68 
TLK1homer4FR4 -74.72  6094.74 -11.26  -17.32 85.70% 77.60% 0.648 
TLK1homer4DFX -54.53 -6539.34  -22.18 -20.69 85.90% 77.10% 0.634 
TLK1homer3SOA -45.31 -5046.76  -4.80 -0.19 81.20% 78.80% 0.625 
TLK1homer4M7N -89.83 -5128.66  -15.31  -0.89 80.80% 79.10% 0.617 
TLK1homer4FGB -79.38 -6276.79  -16.15 -14.23 79.30% 77.50% 0.61 
TLK1homer4L44m -62.07  4967.85 -8.67 -4.86 86.60% 75.60% 0.604 
TLK1homer3Q5I -67.53  5211.28  -3.89 -6.1 77.20% 77.20% 0.596 
TLK1homer4KIKB -46.22 -3504.47 -4.66 -7.84 74.80% 77.20% 0.585 
 TLK1homer3TAC -67.15 -5787.83  -12.33 5.77 81.70% 76.90% 0.582 
 TLK1homer1KOB -67.51 -5454.16 -17.93  10.78 80.30% 77.30% 0.566 
TLK1homer2Y94 -88.61 -5646.09   -14.67 13.09 81.40% 76.30% 0.558 
 TLK1homer2YCF -71.96 -5698.7 -1.22 0.66 76.90% 74.40% 0.551 
TLK1homer4EQC -44.07 -5230.6 -15.55 0.2 79.40% 72.60% 0.511 
TLK1homer3ZDU -20.33 -3543.81 6.09  0.85  79.50% 70.90% 0.509 
TLK1homer2ETR -57.27 -5573.2  -12.92   -18.61 76.30% 68.60% 0.471 
TLK1homer4FIE -48.17 -4413.68  -7.96 -12.1 79.60% 78.60% 0.471 
TLK1homer3I6U -75.46 -6091.17  -6.14  4.72 68.40% 70.50% 0.443 
tlk1model2itasser -211.76 -9701.51 -35.09 43.13 77.80% 65.40% 0.371 
 
 tlk1model1itasser -114.9 -6928.17  -22.73  29.02  71.00% 61.60% 0.294 
QMEAN score of 0.68 out of 1.0 required for an 
excellent homology model (Table 1). The Aurora B 
kinase that in complex with inner centromere protein 
A (VX-680) was determined to 1.85 Å resolution 
(PDB ID: 4B8M). Pro-Motif analysis showed that the 
modelled TLK1 structure, with 270 amino acids, 
contains 4 beta-hairpins, 6-beta bulges, 10 strands, 14 
helices, 15 helix-helix interactions, 16 beta-turns and 
3 gamma turns (Figures 1A and 1B). 
The homology model of TLK1 was also assessed 
using ProSA Z-score. The overall Z-score quality was 
-4.92 suggesting a good quality model compared with 
the available structure from NMR and X-ray (Figures 
2A and 2B). Ramachandran plot obtained from 
PROCHECK analysis achieved a good quality model 
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assessment of 90.1% in the favoured region (Figure 
2C). The plot represents the psi and the phi angles of 
the amino acid residues. Details of the analysis plot 
can be referred to Table 2. Analysis from the 3D 
structural superposition (3d-ss) web server [39] 
showed the root mean square deviation (RMSD) 
between template structure and the 3D homology 
model structure to be 0.543 Å (Figure 2D).  ERRAT 
overall quality factor is 53.696% and at least more than 
80% of the amino acids have scores more than or equal 
to 0.2 in the 3D/1D profile. The YASARA public 
server for energy minimization provided a value of 
16140271100.5 kJ/mol to 143790.2 kJ/mol with a 
score of -1.53 to -0.95. 
 
 
Figure 1. (A) Secondary structure of TLK1 homology model generated from Homology Modeller server. 
Visualization was performed using The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.; b-
sheets, alpha-helices and loops are in yellow, red and green respectively. (B) Depiction of the amino acid residues that 
used in secondary structure analysed from Pro-Motif analysis using PDBsum server. 
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Figure 2. (A) ProSA shows the overall quality model of TLK1 with score of -4.92 (B) ProSA comparison results of 
energy-plots for TLK1 model structure with the PDB ID:  4B8M. (C) Ramachandran plot analysis using PROCHECK 
shows 90.1% of amino acids are generously in the allowed region. (D) 3D structural superposition of Aurora B kinase 
(PDB ID:4B8M) (green) and homology model of TLK1 (yellow). 
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Table 2. Ramachandran plot statistics of TLK1 
homology model structure obtained from 
PROCHECK analysis.  
 
Parameter Value (%) 
 Most favoured region 90.1 
Additional allowed region 8.7 
Generously allowed region 0.4 
Disallowed region 0.8 
Amino acid residues accepted in 
the analysis 
242 out of 
270  
G-factor average score 0.22 
Main chain bond angles 0.41 
Main chain bond lengths 0.62 
 
Proteogenomic analysis 
Functional analysis of the TLK1 modelled structure 
performed using 3d2go web server identified the 
following activities with the highest confidence value 
of 1.0: phosphotransferase activity alcohol group as 
the acceptor, protein amino acid phosphorylation, 
protein serine/threonine kinase activity and nucleotide 
binding. Nucleus and protein binding functions were 
predicted with a confidence value of 0.89. Functional 
prediction in cell cycle, mitosis, phosphoinositide-
mediated signalling (confidence value of 0.86), 
centrosome, spindle organization, regulation of 
protein stability, ubiquitin protein ligase binding 
(confidence value of 0.85) were all in concordance 
with experimental data [40, 41]. These findings were 
predicted to be similar with the function of human 
Aurora kinase2 (PDB ID: 2J4Z). Interestingly, with a 
confidence value of 0.79, the modelled TLK1 structure 
is also predicted to be involved in insulin receptor 
signalling pathway and actin cytoskeleton 
organization which is similar to the human PDK1 
(PDB ID:1UU3). This indicates that TLK1 could be 
involved in the regulation of actin filament 
organization particularly in controlling cancer cell 
motility. 
 
High throughput virtual ligand-docking screening 
The cut-off point of the MolDock docking scoring was 
set at less than -170 to select ligands that predicted to 
have high binding affinity to TLK1. We identified 192 
lead molecules, and ATP was the top scoring molecule 
in the docking procedure with a MolDock score of -
193.654. The amino acid residues that found to 
involve in the protein-ligand interactions were 
GLY463, ARG464, GLY465, GLY466, PHE467, 
SER468, GLU469, VAL470 and LYS485. The 
compounds that utilized in the screening were initially 
not known until we have completed the identification 
procedure. The results showed that ATP docked 
accurately within the cavity, suggesting the robustness 
of the in silico experiment. 
 
In silico pharmacokinetic analysis 
The 192 compounds with the best MolDock scores 
were submitted to the Free ADME-Tox filtering tool 3 
(November 2014 edition) for pharmacokinetic 
analysis. Analysis were subjected to the Lipinski’s 
Rule of Five (RO5) [36] and filters for CNS drugs [37, 
38], to ensure the efficacy and safety of the candidate 
compounds. The final filtering process revealed that 
only two compounds passed this assessment without 
violating the general Lipinski’s RO5 and the CNS rule. 
These compounds were identified as ID352 and 
ID1652 from the ChemBank database (Tables 3 and 
4). Their chemical structures, IUPAC names, the radar 
plot of physicochemical analysis, oral absorption 
estimation data and the Pfizer 3/75 Rule Positioning 
plot, which estimated drug-like molecules that are 
likely to cause toxicity and experimental promiscuity, 
are presented in Figures 3A-H. 
ID1652 is known as beraprost which is a prostacyclin 
analogue used in the treatment of arterial hypertension 
[42]. It has a better docking score, with no violation of 
Lipinki’s rule of five and a low promiscuous toxicity 
as compared to ID352 or bepridil which is a calcium 
channel blocker for anti-angina [43]. Beraprost also 
has a better hydrogen bonding score from the ligand-
docking simulation. Results from receptor-ligand 
interactions (Figure 4) revealed a common cavity for 
ATP, ID352 and ID1652 binding. The residues that are 
involved in the interactions include GLY465, 
GLY466, PHE467, SER468, VAL470, and LYS485. 
These suggested that both of the two compounds bind 
to catalytic site of TLK1 ATP binding pocket. 
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Table 3. Lead molecules with their docking scores and amino acids interaction identified.  
 
*bold fonts: common residues involved in the ATP, Bepridil and Beraprost binding. 
 
Table 4. Physiochemical properties of ligands that passes ADME-TOX Lipinski rule of five and CNS filtering. 
Parameters ID352 ID1652 
MW 366.54 402.52 
logP 5.31 4.1 
logSw -4.94 -4.33 
tPSA 16.91 89.52 
Rotatable bonds 10 10 
Rigid Bonds 17 16 
Flexibility 0.37 0.38 
HB Donors 0 3 
HB Acceptors 3 5 
HBD_HBA 3 8 
Number of system ring 3 1 
Max Size System Ring 6 12 
Charge 1 1 
Total charge 1 -1 
Heavy atoms 27 29 
C atoms 24 24 
Heteroatoms 3 5 
Ratio H/C 0.12 0.21 
Lipinski violation 1 0 
Solubility mg/ml 2613.49 5304.9 
Solubility forecast index Reduced solubility Reduced solubility 
Phospholipidosis Non-inducer Non-inducer 
Stereocenters 1 6 
iPPI No No 
Status Accepted Accepted 
 
Lead 
molecule 
ID 
Chemical 
name 
MolDock 
Score 
Rerank    
Score 
 H-Bond score Amino acids involved in 
interaction* 
 
 
Bepridil -170.518  -109.678  -2.5 GLY465, GLY466, PHE467, 
SER468, VAL470, LYS485, 
HIS487, GLU496, TYR501, 
HIS502, HIS504, ALA505, 
TYR509, GLU508, HIS512, 
LEU523, THR536, LEU538, 
THR606, ASP607, PHE608,  
1652 Befaprost/ 
Beraprost 
-181.124 37.981 -5.35 GLY465, GLY466, PHE467, 
SER468, VAL470, LYS485, 
HIS487, GLU496, TYR501, 
HIS502, HIS504, ALA505, 
CYS506, TYR509, SER528, 
THR533 
*367 
(Control) 
ATP -186.431  -49.1549 -9.386 GLY463, ARG464, GLY465, 
GLY466, PHE467, SER468, 
GLU469, VAL470, LYS485 
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Figure 3. (A) and (B) Structure of identified compounds ID352; N-benzyl-N-(3-isobutoxy-2-pyrrolidin-1-yl-
propyl)aniline and ID1652; 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-
cyclopenta(b)benzofuran-5-butanoic acid respectively. (C) and (D) Physico-chemical profile of compounds ID352 
and ID1652, respectively. A radar plot representing the computed compound profile blue line that should cover within 
the CNS filter area in red and must be within the blue field. (E) and (F) Oral absorption estimation of ID352 and 
ID1652, whereby the compound values should fall within RO5 and Veber rule area; light green and red area. (G) and 
(H) Shows oral bioavailability profile (compound blue dot should fall within the optimal dark green and light green 
area and red ones being extreme zones generally indicating low oral bioavailability). ID352 were predicted to cause 
toxicity compared to ID1652 whereby dot plot falls within the green area which is less likely to cause toxicity. 
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Figure 4. (A) 3D binding mode of the ligands ID1652 in the ATP binding site of the homology modelled TLK1 
protein. The docking pose between ligand 1652 and the ATP binding site of TLK1 protein shows two backbone 
hydrogen bonds between the ligand and TYR501 and GLU496. (B) 2D ligand interaction diagram showing presence 
of hydrophobic interactions between the ligand and PHE467, ALA505, TRY501, CYS506 and TYR509. (C) 3D 
docking pose between ligand 352 and the ATP binding site of TLK1 showing an aromatic-aromatic and amino-
aromatic interactions between the ligands and PHE467 and HIS487 respectively. There is also a hydrogen bond 
between the ligand and the LYS485. (D) 2D ligand interaction diagram showing hydrophobic interactions between 
the ligand and LEU523, LEU538, VAL470, PHE467, TYR501, TYR509, ALA505 and PHE608. The fact that ligand 
ID1652 has more activity than ligand 353 demonstrated the importance of hydrogen bonding rather than the aromatic-
aromatic and amino-aromatic interactions. Visualization of ligand-protein interaction. The three-dimensional and two-
dimensional visualisation of ligand-protein interaction were performed using Maestro software package (Maestro, 
version 10.4, Schrödinger, LLC, New York, NY, 2015). 
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Discussion 
 
GBM remains as the solid tumour with the poorest 
survival in adults since the past few decades. The 
search for the right molecular target is still ongoing 
and one of the many approaches is by using computer-
aided drug discovery tools. Our recent in vitro study 
identified TLK1 as a potential target for glioblastoma 
multiforme. We found TLK1 to be overexpressed and 
the knockdown of TLK1 reduced cellular proliferation 
and invasion [14]. An auto-phosphorylated chemical 
inhibition screen on recombinant TLK1B, which is a 
known splice variant, has been performed by Ronald 
et al, using more than 6,000 compounds. This study 
identified four inhibitors belonging to the class of 
phenothiazine antipsychotics that are structurally and 
chemically similar. The same study also showed that 
thioridazine was able to sensitize prostate cancer cells 
when used with doxorubixin [44]. Although chemical 
library screening for drug discovery seems promising, 
it is very expensive and time consuming. A study 
using the ChemBL database and Kinase SaRfari 
application identified 74 “hits” compounds that can 
potentially bind to TLK1 [45]. However, no details 
were reported on the specific biding sites and the 
specific TLK1 structure that were used for the screen. 
In this study we used a computational approach to 
identify suitable TLK1 inhibitors based on a homology 
model that has been created. 
 
The 3D structure of TLK1 is currently not available 
for drug design strategy, hence we used 18 PDB 
templates that shared 30% to 33% sequence identity, 
to create homology models of TLK1. Thus, Aurora B 
kinase (PDB ID: 4B8M) was identified as the most 
suitable homology template by the HOmology 
modellER server. This model allows us to perform 
ligand-docking analysis to identify potential inhibitors 
for TLK1. 
 
One of the major challenges for optimal therapeutic 
intervention for glioblastoma and other types of brain 
tumor is to achieve maximal penetration across the 
blood brain barrier (BBB). The BBB is a structure 
composed of endothelial cells which is associated with 
perivascular neurons, pericytes and astrocytic end-feet 
processes. The endothelial cells connected by tight 
junctions form an almost impenetrable barrier to all 
compounds except highly lipidized small molecules of 
less than 400 Da [46]. Although many studies have 
identified drug-like molecules from high throughput 
virtual screening, most only follow the Lipinski’s rule 
of five and have neglected the probability calculations 
for the molecules to cross the BBB. This eventually 
led to dismal results in in vivo studies [46–48]. We 
used the recent version of the free ADME-TOX  
 
software and utilized the CNS filter to identify drug-
like molecules that are able to cross the BBB. With this 
approach we identified bepridil and beraprost as the 
two compounds which may bind specifically at the 
catalytic site of TLK1 receptor protein and also 
fulfilled the CNS drugs selection criteria [37, 48]. We 
observed that more than 80% of the interactions 
involved between ligands and receptor are 
hydrophobic. We have also identified other lead 
compounds for TLK1 such as the imidazole-pyrrole 
polyamide derivatives with better binding affinity 
(with Moldock Score of -208.44 to -209.34) compared 
to bepridil and beraprost. Unfortunately, these 
compounds violated the Lipinski’s Rule of Five and 
have molecular masses of more than 450 Da which are 
not suitable to cross the blood brain barrier. 
 
Beraprost, an analogue to prostacyclin or PGI2, is 
commonly used for arterial pulmonary hypertension 
and has multiple physiological effects such as 
endothelial vasodilation, inhibition of platelet 
aggregation, leukocyte adhesion, and vascular smooth 
muscle cell proliferation [49]. Activation of the PGI2 
signalling pathway by beraprost sodium suppressed 
lung cancer metastases by preventing maturation of 
angiogenesis [50]. It was also reported to enhance 
permeability and retention (EPR) of solid tumors by 
decreasing tumor blood flow by 70%, hence inhibiting 
tumor growth. Furthermore, it did not affect normal 
cells and systemic blood flow [51]. Since this 
compound mimics structurally related lipid soluble 
hormone PGI2, it was predicted that the efficacy of the 
compound will be high as it will be able to cross the 
BBB [52]. 
 
Bepridil is a known sodium-calcium channel blocker 
that is use for anti-arrhythmias. An earlier study 
reported that bepridil caused tumor growth inhibition 
in neuroblastoma and astrocytoma cells by causing a 
prolonged increase in free intracellular calcium 
concentration when cells were co-treated with anti-
estrogens [53]. Bepridil has been experimentally 
found to bind to the N-domain pocket of cardiac 
troponin C but with negative cooperativity [54]. Even 
though, theoretically, bepridil can cross blood brain 
barrier effectively [55], our findings showed that it 
may have non-specific binding properties towards 
TLK1. Hence, it will be an added value if some 
chemical modification can be made to increase its 
selectivity towards TLK1. It is worth to note that S-
bepridil was found to have a higher binding affinity 
towards the p53 binding domain in MDM2 [56]. In 
order to enhance binding affinity between TLK1 
receptor and these two identified ligands, as well as 
preventing cross binding towards other types of 
receptors, modification of current ligand structure by  
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QSAR fragment based on pharmacophore analysis is 
warranted for future study. 
 
This study has identified potential inhibitors that binds 
at the catalytic site of TLK1. However, identification 
of inhibitors that can bind to the non-catalytic 
component of a particular kinase would also be useful 
as they would also play significant roles in the 
regulation of cellular functions [57]. Further studies of 
TLK-ligand complex structure will allow 
identification of allosteric inhibition sites to provide 
much specific TLK1 regulatory inhibitory effects. 
 
 
Conclusion 
 
We have successfully created a 3D structure for the 
catalytic domain for TLK1 which was predicted to be 
a potential molecular target for GBM. We have 
performed vigorous analysis to determine the 
suitability and stability of the modelled structure 
through various quality control platforms. We 
identified beraprost and bepridil as the two candidate 
compounds that will bind to TLK1. These two drugs 
are commonly used for cardiovascular diseases. 
Further in vitro and in vivo studies need to be 
performed to validate the therapeutic value of these 
compounds for GBM. 
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